Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses several trials presented at ASH 2020 that aim to address unmet needs in the treatment of amyloidosis. Given the lack of established therapies that target amyloid deposits, a 3+3 dose escalation study (NCT04304144) investigated the CAEL101 antibody, which binds to these deposits and activates macrophages to reduce the amyloid burden. The trial determined a recommended phase II dose for further investigation. Treatment of stage 3b amyloidosis, where outcomes are extremely poor, is another unmet need. A trial (NCT03499808) was discussed at ASH 2020 that looked at isatuximab, an anti-CD38 antibody, in the relapsed/refractory setting. Promising response and safety findings were reported, warranting ongoing investigation. Dr Gertz also shares advancements in the understanding of outcome prediction in light chain amyloidosis. A recent investigation found that change in the involved light chain or the difference between involved and uninvolved light chain were major predictors of progression free survival, unlike the light chain ratio. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть